DK0729473T3 - Glucosamin-disaccharider, fremgangsmåde til deres fremstilling farmaceutisk sammensætning deraf og deres anvendelse - Google Patents

Glucosamin-disaccharider, fremgangsmåde til deres fremstilling farmaceutisk sammensætning deraf og deres anvendelse

Info

Publication number
DK0729473T3
DK0729473T3 DK95903265T DK95903265T DK0729473T3 DK 0729473 T3 DK0729473 T3 DK 0729473T3 DK 95903265 T DK95903265 T DK 95903265T DK 95903265 T DK95903265 T DK 95903265T DK 0729473 T3 DK0729473 T3 DK 0729473T3
Authority
DK
Denmark
Prior art keywords
disaccharides
pct
pharmaceutical composition
date
lipid
Prior art date
Application number
DK95903265T
Other languages
English (en)
Inventor
Pierre Hirt
Adrian Schulthess
John Gwynfor Davies
Jacques Bauer
Original Assignee
Deutsche Om Arzneimittel Gmbh
Om Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deutsche Om Arzneimittel Gmbh, Om Pharma filed Critical Deutsche Om Arzneimittel Gmbh
Application granted granted Critical
Publication of DK0729473T3 publication Critical patent/DK0729473T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
    • C07H13/06—Fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK95903265T 1993-11-17 1994-11-17 Glucosamin-disaccharider, fremgangsmåde til deres fremstilling farmaceutisk sammensætning deraf og deres anvendelse DK0729473T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP93203223 1993-11-17
PCT/EP1994/003852 WO1995014026A1 (en) 1993-11-17 1994-11-17 Glucosamine disaccharides, method for their preparation, pharmaceutical composition comprising same, and their use

Publications (1)

Publication Number Publication Date
DK0729473T3 true DK0729473T3 (da) 2000-10-30

Family

ID=8214175

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95903265T DK0729473T3 (da) 1993-11-17 1994-11-17 Glucosamin-disaccharider, fremgangsmåde til deres fremstilling farmaceutisk sammensætning deraf og deres anvendelse

Country Status (22)

Country Link
US (1) US6005099A (da)
EP (1) EP0729473B1 (da)
JP (1) JP3967769B2 (da)
KR (1) KR100355470B1 (da)
CN (1) CN1055093C (da)
AT (1) ATE195740T1 (da)
AU (1) AU700485B2 (da)
BR (1) BR9408071A (da)
CA (1) CA2175375C (da)
CZ (1) CZ290331B6 (da)
DE (1) DE69425671T2 (da)
DK (1) DK0729473T3 (da)
ES (1) ES2149340T3 (da)
GR (1) GR3034872T3 (da)
HU (1) HU219810B (da)
PL (1) PL181241B1 (da)
PT (1) PT729473E (da)
RO (1) RO115731B1 (da)
RU (1) RU2154068C2 (da)
SI (1) SI0729473T1 (da)
SK (1) SK281944B6 (da)
WO (1) WO1995014026A1 (da)

Families Citing this family (131)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2337807C (fr) * 1998-06-30 2012-08-21 Om Pharma Nouveaux pseudodipeptides acyles, leur mode de preparation et les compositions pharmaceutiques en renfermant
WO2000047595A1 (fr) 1999-02-10 2000-08-17 Sankyo Company, Limited Analogues de type ether d'acide a1-carboxylique lipidique
US7776343B1 (en) 1999-02-17 2010-08-17 Csl Limited Immunogenic complexes and methods relating thereto
WO2001036433A2 (en) * 1999-11-15 2001-05-25 Biomira, Inc. Synthetic lipid-a analogs and uses thereof
KR100898844B1 (ko) * 1999-12-22 2009-05-21 옴 파르마 작용기화된 보조 아암을 가진 아실 슈도디펩티드
WO2001046127A1 (fr) * 1999-12-22 2001-06-28 Om Pharma Pseudodipeptides acyles porteurs d'un bras auxiliaire fonctionnalise
PL211151B1 (pl) 2000-10-18 2012-04-30 Glaxosmithkline Biolog Sa Kompozycja immunogenna oraz zastosowanie połączenia saponiny, oligonukleotydu immunostymulującego i lipopolisacharydu
KR100465229B1 (ko) * 2001-04-09 2005-01-13 주식회사 안지오랩 2-아미노-2-데옥시-ｄ-글루코피라노오즈 또는 그의약학적으로 허용가능한 염을 유효성분으로 하는 혈관신생억제용 약학적 조성물
EP1528937B1 (en) * 2001-06-05 2016-08-10 The Regents Of The University Of Michigan Nanoemulsion vaccines
US8232255B2 (en) 2002-10-23 2012-07-31 Glaxosmithkline Biologicals S.A. Methods for vaccinating against malaria
GB0321615D0 (en) 2003-09-15 2003-10-15 Glaxo Group Ltd Improvements in vaccination
WO2005117958A1 (en) 2004-05-28 2005-12-15 Glaxosmithkline Biologicals S.A. Vaccine compositions comprising virosomes and a saponin adjuvant
WO2006095270A1 (en) * 2005-03-10 2006-09-14 Om Pharma Combination anticancer therapy or om-174 and pharmaceutical compositions therefor
EP1773318A1 (en) * 2004-07-23 2007-04-18 OM Pharma Combination anticancer therapy and pharmaceutical compositions therefor
GB0417494D0 (en) 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine
US20060210590A1 (en) 2005-02-03 2006-09-21 Alk-Abello A/S Minor allergen control to increase safety of immunotherapy
GB0503337D0 (en) 2005-02-17 2005-03-23 Glaxosmithkline Biolog Sa Compositions
US20090081253A1 (en) 2005-03-23 2009-03-26 Glaxosmithkline Biologicals S.A. Composition
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
NZ569168A (en) 2005-12-22 2012-02-24 Glaxosmithkline Biolog Sa Streptococcus pneumoniae polysaccharide conjugate vaccine comprising 19F-DT conjugate
SG170090A1 (en) 2006-03-30 2011-04-29 Glaxosmithkline Biolog Sa Immunogenic composition
KR100780868B1 (ko) * 2006-07-10 2007-11-30 부경대학교 산학협력단 항암효과를 나타내는 4급 아미노 글루코사민 화합물
ES2525572T3 (es) 2006-07-17 2014-12-26 Glaxosmithkline Biologicals S.A. Vacuna antigripal
NZ574239A (en) 2006-07-18 2011-12-22 Glaxosmithkline Biolog Sa Hybrid fusion proteins for malaria vaccines
WO2008012538A2 (en) 2006-07-25 2008-01-31 The Secretary Of State For Defence Live vaccine strains of francisella
PT2468300T (pt) 2006-09-26 2018-01-30 Infectious Disease Res Inst Composição para vacina contendo adjuvante sintético
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
PL2086582T3 (pl) 2006-10-12 2013-04-30 Glaxosmithkline Biologicals Sa Kompozycja zawierająca adiuwant w postaci emulsji typu olej w wodzie
WO2008059307A2 (en) * 2006-11-16 2008-05-22 Om Pharma Functionalized beta 1,6 glucosamine disaccharides and process for their preparation
CN103550764A (zh) 2007-03-02 2014-02-05 葛兰素史密丝克莱恩生物有限公司 疫苗组合物及其在刺激免疫反应中的用途
CN101663041B (zh) 2007-03-05 2012-05-23 Om药物公司 用于呼吸病症的细菌提取物及其制备方法
AR066405A1 (es) 2007-04-20 2009-08-19 Glaxosmithkline Biolog Sa Vacuna
KR101579947B1 (ko) 2007-06-26 2015-12-28 글락소스미스클라인 바이오로지칼즈 에스.에이. 스트렙토코쿠스 뉴모니애 캡슐 다당류 컨쥬게이트를 포함하는 백신
ES2626634T3 (es) 2007-12-19 2017-07-25 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Formas solubles de la glucoproteína F del virus de Hendra y Nipah y usos de la misma
SG188813A1 (en) 2007-12-24 2013-04-30 Id Biomedical Corp Quebec Recombinant rsv antigens
ES2678694T3 (es) 2008-04-16 2018-08-16 Glaxosmithkline Biologicals Sa Vacuna
CA2725381A1 (en) * 2008-05-23 2010-03-25 The Regents Of The University Of Michigan Nanoemulsion adjuvants
US9415006B2 (en) 2008-05-23 2016-08-16 The Regents Of The University Of Michigan Immunogenic compositions comprising nanoemulsion and hepatitis B virus immunogen and methods of using the same
CN102123724B (zh) 2008-06-19 2018-05-01 变异生技公司 治疗流行性感冒的组合物和方法
JP5722782B2 (ja) 2008-09-26 2015-05-27 ナノバイオ コーポレーション ナノエマルジョン治療用組成物及びその使用方法
AU2009323996A1 (en) 2008-12-03 2011-07-07 Institut Pasteur Use of phenol-soluble modulins for vaccine development
WO2010079081A1 (en) 2009-01-07 2010-07-15 Glaxosmithkline Biologicals S.A. Methods for recovering a virus or a viral antigen produced by cell culture
GB0901411D0 (en) 2009-01-29 2009-03-11 Secr Defence Treatment
GB0901423D0 (en) 2009-01-29 2009-03-11 Secr Defence Treatment
JP5843615B2 (ja) 2009-02-06 2016-01-13 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 密度勾配超遠心分離によるウイルスまたはウイルス抗原の精製
PE20110992A1 (es) 2009-02-17 2012-02-12 Glaxosmithkline Biolog Sa Composicion inmunogenica que comprende un antigeno del virus del dengue
GB0906234D0 (en) 2009-04-14 2009-05-20 Secr Defence Vaccine
US20110097418A1 (en) * 2009-05-29 2011-04-28 Variation Biotechnologies, Inc. Compositions and methods for treating influenza
DK2437753T3 (da) 2009-06-05 2016-12-19 Infectious Disease Res Inst Syntetiske glucopyranosyl-lipid-adjuvanser og vaccinesammensætninger, der indeholder dem
EP2442827B1 (en) 2009-06-16 2016-01-06 The Regents of the University of Michigan Nanoemulsion vaccines
KR20120093811A (ko) 2009-06-24 2012-08-23 아이디 바이오메디컬 코포레이션 오브 퀘벡 백신
AU2010264688A1 (en) 2009-06-24 2012-01-19 Glaxosmithkline Biologicals S.A. Recombinant RSV antigens
WO2011005772A1 (en) 2009-07-06 2011-01-13 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
AU2010270722B2 (en) 2009-07-06 2015-06-04 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
HRP20220756T1 (hr) 2009-07-15 2022-09-02 Glaxosmithkline Biologicals S.A. Proteinski pripravci rsv f i postupci za izradu istih
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
US9341623B2 (en) 2009-09-25 2016-05-17 Glaxosmithkline Biologicals Sa Immunodiffusion assay for influenza virus
GB0919117D0 (en) 2009-10-30 2009-12-16 Glaxosmithkline Biolog Sa Process
WO2011101332A1 (en) 2010-02-16 2011-08-25 Proyecto De Biomedicina Cima, S.L. Compositions based on the fibronectin extracellular domain a for the treatment of melanoma
US20110229512A1 (en) * 2010-03-19 2011-09-22 The Regents Of The University Of Michigan Compositions and methods for diagnosing and treating urinary tract infections
US20130039943A1 (en) 2010-05-03 2013-02-14 Bruno Rene Andre Novel method
GB201009273D0 (en) 2010-06-03 2010-07-21 Glaxosmithkline Biolog Sa Novel vaccine
US8658603B2 (en) 2010-06-16 2014-02-25 The Regents Of The University Of Michigan Compositions and methods for inducing an immune response
CA2840079C (en) 2010-07-06 2018-07-03 Variation Biotechnologies Inc. Compositions and methods for treating influenza
BR112013004582A2 (pt) 2010-09-27 2016-09-06 Crucell Holland Bv método para induzir uma resposta imune em um sujeito contra um antígeno de um parasita que causa a malária
EP2627352B1 (en) 2010-10-15 2017-05-10 GlaxoSmithKline Biologicals S.A. Cytomegalovirus gb antigen
AU2012205315B2 (en) 2011-01-13 2017-05-04 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
BR112013017939B1 (pt) 2011-01-13 2022-11-16 Variation Biotechnologies Inc Composição imunogênica liofilizada termoestável, uso e método para preparação da mesma
EP2505640A1 (en) 2011-03-29 2012-10-03 Neo Virnatech, S.L. Vaccine compositions for birnavirus-borne diseases
CA2832307A1 (en) 2011-04-08 2012-10-18 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
MX339058B (es) 2011-05-17 2016-05-09 Glaxosmithkline Biolog Sa Vacuna contra streptococcus pneumoniae.
WO2013038156A1 (en) 2011-09-16 2013-03-21 Ucb Pharma S.A. Neutralising antibodies to the major exotoxins tcda and tcdb of clostridium difficile
EP2780034A1 (en) 2011-11-14 2014-09-24 Crucell Holland B.V. Heterologous prime-boost immunization using measles virus-based vaccines
WO2013104995A2 (en) 2012-01-12 2013-07-18 Variation Biotechnologies, Inc. Compositions and methods for treating viral infections
CA2894467A1 (en) 2012-01-27 2013-08-01 Variation Biotechnologies Inc. Methods for preparing thermostable compositions comprising a lipid component and thermolabile therapeutic agents
EP2827891A1 (en) 2012-03-18 2015-01-28 GlaxoSmithKline Biologicals S.A. Method of vaccination against human papillomavirus
US9241988B2 (en) * 2012-04-12 2016-01-26 Avanti Polar Lipids, Inc. Disaccharide synthetic lipid compounds and uses thereof
US9518078B2 (en) * 2012-04-12 2016-12-13 Avanti Polar Lipids, Inc. Disaccharide synthetic lipid compounds and uses thereof
EP2850431B1 (en) 2012-05-16 2018-04-18 Immune Design Corp. Vaccines for hsv-2
WO2014024026A1 (en) 2012-08-06 2014-02-13 Glaxosmithkline Biologicals S.A. Method for eliciting in infants an immune response against rsv and b. pertussis
US20140037680A1 (en) 2012-08-06 2014-02-06 Glaxosmithkline Biologicals, S.A. Novel method
US10058603B2 (en) 2013-03-15 2018-08-28 Glaxosmithkline Biologicals S.A. Vaccine
CA2909221A1 (en) 2013-04-18 2014-10-23 Immune Design Corp. Gla monotherapy for use in cancer treatment
EA031879B1 (ru) * 2013-06-04 2019-03-29 Пётр Геннадиевич Апарин Модифицированный липополисахарид эндотоксичных бактерий (варианты), комбинация модифицированных липополисахаридов (варианты) и включающие их вакцина (варианты) и фармацевтическая композиция (варианты)
US9463198B2 (en) * 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
US11052142B2 (en) * 2013-06-04 2021-07-06 Petr G. Aparin Modified endotoxic bacteria lipopolysaccharide (variants), combination of modified lipopolysaccharides (variants) and, containing same, a vaccine (variants) and a pharmaceutical composition (variants)
BE1022008B1 (fr) 2013-08-05 2016-02-03 Glaxosmithkline Biologicals S.A. Compositions immunogenes combinees
CN105473712B (zh) 2013-08-30 2022-05-27 葛兰素史密丝克莱恩生物有限公司 在细胞培养物中大规模生产病毒
CN104436157A (zh) 2013-09-23 2015-03-25 恩金生物有限公司 流感疫苗和治疗
CA2928700C (en) 2013-11-01 2019-01-15 University Of Oslo Albumin variants and uses thereof
US11452767B2 (en) 2013-11-15 2022-09-27 Oslo Universitetssykehus Hf CTL peptide epitopes and antigen-specific t cells, methods for their discovery, and uses thereof
WO2015092710A1 (en) 2013-12-19 2015-06-25 Glaxosmithkline Biologicals, S.A. Contralateral co-administration of vaccines
EP3110401A4 (en) 2014-02-25 2017-10-25 Merck Sharp & Dohme Corp. Lipid nanoparticle vaccine adjuvants and antigen delivery systems
WO2015165480A1 (en) 2014-04-30 2015-11-05 Institute For Research In Biomedicine Human cytomegalovirus vaccine compositions and method of producing the same
MX2016016533A (es) 2014-06-13 2017-05-01 Glaxosmithkline Biologicals Sa Combinaciones inmunogenas.
JP7158853B2 (ja) 2014-10-10 2022-10-24 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 対象における食物アレルギーまたは呼吸器アレルギーを処置するための、かつ上記対象の鼻腔内に投与するための免疫原性組成物
US10813993B2 (en) 2015-03-03 2020-10-27 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Display platform from bacterial spore coat proteins
EP4226936A3 (en) 2015-03-05 2023-09-27 Northwestern University Non-neuroinvasive viruses and uses thereof
WO2016207730A1 (en) 2015-06-22 2016-12-29 The University Of Oslo Targeting of vaccine antigen to an intracellular compartment
US20180186897A1 (en) 2015-06-26 2018-07-05 Institute For Research In Biomedicine Novel vaccines in prevention and treatment of malaria
WO2017158421A1 (en) 2016-03-14 2017-09-21 University Of Oslo Anti-viral engineered immunoglobulins
TN2018000301A1 (en) 2016-03-14 2020-01-16 Univ Oslo Engineered immunoglobulins with altered fcrn binding
US11173207B2 (en) 2016-05-19 2021-11-16 The Regents Of The University Of Michigan Adjuvant compositions
WO2017221072A2 (en) 2016-06-21 2017-12-28 University Of Oslo Hla binding vaccine moieties and uses thereof
US11498956B2 (en) 2016-08-23 2022-11-15 Glaxosmithkline Biologicals Sa Fusion peptides with antigens linked to short fragments of invariant chain(CD74)
GB201614799D0 (en) 2016-09-01 2016-10-19 Glaxosmithkline Biologicals Sa Compositions
BE1024774B1 (fr) 2016-09-29 2018-07-02 Glaxosmithkline Biologicals Sa Compositions et procedes de traitement
WO2018096396A1 (en) 2016-11-22 2018-05-31 University Of Oslo Albumin variants and uses thereof
GB201620968D0 (en) 2016-12-09 2017-01-25 Glaxosmithkline Biologicals Sa Adenovirus polynucleotides and polypeptides
CA3043790A1 (en) 2016-12-16 2018-06-21 Institute For Research In Biomedicine Novel recombinant prefusion rsv f proteins and uses thereof
WO2018162450A1 (en) 2017-03-06 2018-09-13 Fundación Para La Investigación Médica Aplicada New inmunostimulatory compositions comprising an entity of cold inducible rna-binding protein with an antigen for the activation of dendritic cells
CA3058979A1 (en) 2017-04-19 2018-10-25 Institute For Research In Biomedicine Novel malaria vaccines and antibodies binding to plasmodium sporozoites
CA3066020A1 (en) 2017-06-16 2018-12-20 Glaxosmithkline Biologicals Sa Method of treatment
WO2019048928A1 (en) 2017-09-07 2019-03-14 University Of Oslo VACCINE MOLECULES
US12005112B2 (en) 2017-09-07 2024-06-11 University Of Oslo Vaccine molecules
CN111315406A (zh) 2017-09-08 2020-06-19 传染病研究所 包括皂苷的脂质体调配物及其使用方法
GB201721069D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B Immunisation regimen and compositions
GB201721068D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B immunisation regimen and compositions
CN111867623B (zh) 2018-02-12 2024-06-04 英尼穆内公司 Toll样受体配体
BR112020024285A2 (pt) 2018-06-12 2021-03-02 Glaxosmithkline Biologicals S.A. polinucleotídeos e polipeptídeos de adenovírus
EP3581201A1 (en) 2018-06-15 2019-12-18 GlaxoSmithKline Biologicals S.A. Escherichia coli o157:h7 proteins and uses thereof
MX2021001479A (es) 2018-08-07 2021-04-28 Glaxosmithkline Biologicals Sa Novedosos procesos y vacunas.
US20220184158A1 (en) 2018-12-21 2022-06-16 Glaxosmithkline Biologicals Sa Methods of inducing an immune response
CN113573730A (zh) 2019-03-05 2021-10-29 葛兰素史密斯克莱生物公司 乙型肝炎免疫方案和组合物
US20230201334A1 (en) 2019-07-24 2023-06-29 Glaxosmithkline Biologicals Sa Modified human cytomegalovirus proteins
CA3202549A1 (en) 2020-12-02 2022-06-09 Glaxosmithkline Biologicals Sa Novel antigens
WO2022161598A1 (en) 2021-01-26 2022-08-04 Eth Zurich Antibodies broadly targeting coronaviruses and uses thereof
WO2022162012A2 (en) 2021-01-26 2022-08-04 Eth Zurich Antibodies broadly targeting coronaviruses and uses thereof
WO2023114727A1 (en) 2021-12-13 2023-06-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Bacteriophage lambda-vaccine system
WO2023144665A1 (en) 2022-01-28 2023-08-03 Glaxosmithkline Biologicals Sa Modified human cytomegalovirus proteins
WO2024133160A1 (en) 2022-12-19 2024-06-27 Glaxosmithkline Biologicals Sa Hepatitis b compositions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8501582A (nl) * 1985-02-12 1986-09-01 Philips Nv Videosignaalverwerkingsschakeling voor de verwerking van een geinterlinieerd videosignaal.
GR860379B (en) * 1985-02-22 1986-06-11 Akzo Nv Novel disaccharide and trisaccharide derivatives of the lipid a type
US4912094B1 (en) * 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5158939A (en) * 1989-07-21 1992-10-27 Wisconsin Alumni Research Foundation Method of stimulating the immune systems of animals and compositions useful therefor
JPH06206893A (ja) * 1992-09-07 1994-07-26 Suntory Ltd 新規なジサッカライド誘導体

Also Published As

Publication number Publication date
RU2154068C2 (ru) 2000-08-10
AU700485B2 (en) 1999-01-07
SK281944B6 (sk) 2001-09-11
US6005099A (en) 1999-12-21
SK61396A3 (en) 1996-11-06
BR9408071A (pt) 1996-12-24
CN1055093C (zh) 2000-08-02
HU219810B (hu) 2001-08-28
SI0729473T1 (en) 2001-02-28
WO1995014026A1 (en) 1995-05-26
CZ141896A3 (en) 1996-10-16
PL181241B1 (pl) 2001-06-29
PT729473E (pt) 2001-02-28
ES2149340T3 (es) 2000-11-01
EP0729473B1 (en) 2000-08-23
AU1219495A (en) 1995-06-06
KR100355470B1 (ko) 2003-02-17
CA2175375C (en) 2010-01-05
EP0729473A1 (en) 1996-09-04
CN1137799A (zh) 1996-12-11
DE69425671T2 (de) 2001-04-19
HU9601312D0 (en) 1996-07-29
CA2175375A1 (en) 1995-05-26
GR3034872T3 (en) 2001-02-28
RO115731B1 (ro) 2000-05-30
CZ290331B6 (cs) 2002-07-17
HUT74738A (en) 1997-02-28
ATE195740T1 (de) 2000-09-15
DE69425671D1 (de) 2000-09-28
JP3967769B2 (ja) 2007-08-29
JPH09505071A (ja) 1997-05-20
PL314494A1 (en) 1996-09-16

Similar Documents

Publication Publication Date Title
DK0729473T3 (da) Glucosamin-disaccharider, fremgangsmåde til deres fremstilling farmaceutisk sammensætning deraf og deres anvendelse
UA70298A (uk) Похідні с-4"-заміщених макролідів, спосіб їх одержання, проміжні сполуки, фармацевтична композиція та спосіб лікування бактеріальної інфекції або протозойної інфекції
PL314188A1 (en) Novel derivatives of benzoguanidine, method of obtaining them and their application in pharmaceutical compositions
BR9711135A (pt) Composto composi-Æo farmac-utica utiliza-Æo de um composto e processos para prepara-Æo de um composto e para inibi-Æo de Äxido-equaleno ciclase num animal de sangue quente requerendo um tal tratamento
ATE255589T1 (de) Kristallin form i von clarithromycin
DK0712396T3 (da) Substituerede azadioxacycloalkener og deres anvendelse som fungicider
HUT72436A (en) Process for the production of imidazopyridines and pharmaceutical compositions containing them and which are suitable for treating gastro-intestinal diseases
BR9714287A (pt) Antibiótico cristalino designado solvato 6-o-metileritromicina forma 0, solvato de 6-o-metileritromicina forma 0, composição, processos para tratamento de infecções bacterianas em um mamìfero hospedeiro com necessidade de tal tratamento e para preparação de solvato de 6-o-metileritomicina a forma 0, 6-o-metileritromicina forma 0--etanolato, suspensão para administração oral, e, complexo de solvato de 6-o-metileritromicina a forma 0-carbÈmero.
BG104644A (en) Novel macrolides
PL315973A1 (en) Compositions containing micronised nebivolol
IL113160A (en) Lipopeptide a1437 derivatives a process for their preparation and pharmaceutical compositions containing them
YU40900A (sh) Novi derivati eritromicina
HUT60713A (en) Process for producing pharmaceutical compositions suitable for treating hiv infections and for producing their active ingredients
MY122353A (en) 13-membered azalides and their use as antibiotic agents
CA2123232A1 (fr) Compositions pharmaceutiques a base d'ebastine ou de ses analogues
UA41871C2 (uk) Похідні еритроміцину, спосіб їх одержання та фармацевтична композиція на їх основі
BR9610175A (pt) Composto processo de preparação do composto composição farmacêutica e utilização do composto
AP9801235A0 (en) Erythromycin derivatives.
GR3025050T3 (en) Etoposide derivatives, process for their preparation, their use as a drug and in the preparation of a drug for treating cancer.
IE43125L (en) Aminoglycoside derivative
KR870008910A (ko) 돼지 이질의 예방 및 치료제
UA48982C2 (uk) Поліморфи проліків тровафлоксацину, спосіб їх отримання, спосіб лікування бактеріальної інфекції і фармацевтична композиція
IL110025A0 (en) Phosphonosuccinic acid derivatives, processes for the preparation thereof and pharmaceutical compositions containing them